Efficacy of Betaine for Reduction of Urine Oxalate in Patients With Type 1 Primary Hyperoxaluria
Status:
Completed
Trial end date:
2011-09-01
Target enrollment:
Participant gender:
Summary
The aim of this study is to assess the efficacy and safety of betaine in reducing urine
oxalate excretion of Type 1 Primary Hyperoxaluria (PHI) patients.
Hypothesis:
Betaine will effectively reduce urine oxalate excretion in Primary Hyperoxaluria Type I
patients.
Phase:
Phase 2
Details
Lead Sponsor:
Mayo Clinic
Collaborators:
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) Orphan Europe